{
    "Allocation": "Randomized",
    "CompleteTime": 50,
    "DesignModel": "Parallel Assignment",
    "DrugInformation": {
        "ArmGroupList": [
            {
                "ArmGroupDescription": "hmpl-523(300mg po qd):   , ",
                "ArmGroupLabel": "HMPL-523",
                "ArmGroupType": "Experimental",
                "InterventionDescription": [
                    {
                        "Dosage": "",
                        "DrugName": "hmpl-523(300mg po qd)",
                        "Duration": "",
                        "HowToTake": "",
                        "OtherName": [
                            "Sovleplenib"
                        ]
                    }
                ],
                "InterventionList": {
                    "ArmGroupInterventionName": [
                        "drug: hmpl-523(300mg po qd)"
                    ]
                }
            },
            {
                "ArmGroupDescription": "placebo:   , ",
                "ArmGroupLabel": "Placebo",
                "ArmGroupType": "Placebo Comparator",
                "InterventionDescription": [
                    {
                        "Dosage": "",
                        "DrugName": "placebo",
                        "Duration": "",
                        "HowToTake": "",
                        "OtherName": []
                    }
                ],
                "InterventionList": {
                    "ArmGroupInterventionName": [
                        "drug: placebo"
                    ]
                }
            }
        ]
    },
    "Enrollment": "110",
    "InterventionName": "Placebo",
    "Masking": "Quadruple",
    "NCTID": "NCT05535933",
    "Objective": "HMPL-523 (Sovleplenib) in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia",
    "OfficialTitle": "A Randomized, Double-Blind, Placebo-Controlled Phase II/III Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of HMPL-523 in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia",
    "PopulationBox": {
        "Condition": "Warm Antibody Autoimmune Hemolytic Anemia",
        "Gender": "All",
        "HealthyCondition": "No",
        "MaxAge": "75 Years",
        "MinAge": "18 Years",
        "Participant": "110"
    },
    "PopulationRatio": "",
    "Title": "HMPL-523 (Sovleplenib) in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia",
    "WashoutPeriod": "",
    "_id": "NCT05535933",
    "version": "1.7.1"
}